Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Open-Label, Two-Stage Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral AKT Inhibitor GSK2110183 in Subjects With Any Hematologic Malignancy.

Next Previous
Trial Profile

A Phase I, Open-Label, Two-Stage Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral AKT Inhibitor GSK2110183 in Subjects With Any Hematologic Malignancy.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 24 Jul 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Afuresertib (Primary)
  • Indications Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Haematological malignancies; Hodgkin's disease; Multiple myeloma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; First in man; Pharmacokinetics

Most Recent Events

  • 03 Apr 2012 Actual patient number 73 added as reported by ClinicalTrials.gov.
  • 03 Apr 2012 Additional trial location (South Korea) identified as reported by ClinicalTrials.gov.
  • 03 Apr 2012 Actual end date Mar 2012 added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top